Influence of hydroxyethyl starch (6% HES 130/0.4) administration on hematology and clinical chemistry parameters by Mueller, Thomas et al.
Clin Chem Lab Med 2008;46(4):558–562  2008 by Walter de Gruyter • Berlin • New York. DOI 10.1515/CCLM.2008.107 2007/335
Article in press - uncorrected proof
Short communication
Influence of hydroxyethyl starch (6% HES 130/0.4)
administration on hematology and clinical chemistry
parameters
Thomas Mueller1,*, Wolfgang Schimetta2,
Benjamin Dieplinger1, Peter Loeffler3, Markus
Rehm4, Uwe Kreimeier4, Werner Poelz2 and
Meinhard Haltmayer1,5
1 Department of Laboratory Medicine,
Konventhospital Barmherzige Brueder, Linz, Austria
2 Department of Applied System Sciences and
Statistics, University of Linz, Linz, Austria
3 Department of Otorhinolaryngology,
Konventhospital Barmherzige Brueder, Linz, Austria
4 Clinic of Anesthesiology, Ludwig-Maximilians
University, Klinikum Grosshadern, Munich, Germany
5 Paracelsus Private Medical University, Salzburg,
Austria
Abstract
Background: The chemical inertness of hydroxyethyl
starch (HES) might cause interferences of the colloid
with a variety of laboratory tests. We aimed to eval-
uate potential influences of HES 130/0.4, the newest
HES type, on several common hematology and clini-
cal chemistry parameters.
Methods and results: A convenient sample of 25
patients scheduled for rheological therapy with
500 mL 6% HES 130/0.4 was evaluated. Blood sam-
ples were drawn before and after colloid application.
Comparing pre- and post-infusion values of a battery
of laboratory tests (i.e., hematology and hemostasis
parameters, electrolytes, enzymes, kidney and meta-
bolic parameters, lipids, etc.) in time course, a median
difference greater than the reference change value for
a specific parameter was considered clinically rele-
vant. Among all parameters tested, only serum amy-
lase activity displayed a clinically relevant difference
between pre- and post-infusion values (median
increase of 85% due to HES administration). By apply-
ing in vitro experiments, we demonstrated that serum
amylase values obtained in the samples diluted in a
1:1 ratio with HES 130/0.4 and in samples diluted in a
1:1 ratio with 0.9% NaCl displayed a negligible medi-
an difference of 3%.
Conclusions: The in vivo effect of HES 130/0.4 admin-
istration on serum amylase activity observed in our
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study was pharmacological (real) in nature. With the
exception of the influence of HES 130/0.4 on amylase
activity, the effects of HES 130/0.4 on other parame-
ters tested in this study can be interpreted as having
no clinical relevance.
Clin Chem Lab Med 2008;46:558–62.
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Hydroxyethyl starch (HES) solutions are the most
common plasma substitutes in Europe and more and
more also in other parts of the world (1). The various
types of HES differ in degree and position of
hydroxyethylation and in average molecular weight
(2). Some years ago, a newly designed third-genera-
tion HES type, called HES 130/0.4, was introduced into
the market (2). HES 130/0.4 has improved elimination
properties and optimized influences on the micro-
circulation compared to older HES types (3–5). As a
consequence of the new pharmacological profile, the
deterioration of coagulation, a well-known side effect
of older HES types, has almost completely disap-
peared (6–14). Similar to all other HES types, HES
130/0.4 also elevates serum amylase concentration
(9, 12). This effect is explained by the generation of
HES-amylase complexes impeding the renal excretion
of amylase and, thus, inducing accumulation (15, 16).
Besides the genuine influence on several laboratory
parameters, HES is also able to influence the results
of specific measurements (17–23). Although these
observations were made for specific HES types only,
it is possible that these effects may also occur in other
HES preparations.
As the chemical inertness of HES might cause inter-
ferences of the colloid with a variety of laboratory
tests in vivo and in vitro, we aimed to evaluate poten-
tial influences of HES 130/0.4, the newest HES type
which is now already in widespread use, on several
common hematology and clinical chemistry para-
meters.
The present single center study was performed pro-
spectively at the St. John of God Hospital Linz, Aus-
tria. The study protocol was approved by the Local
Ethics Committee in accordance with the Declaration
of Helsinki, and written informed consent was
obtained from all study participants. To determine
possible changes in hematology and clinical chemis-
try parameters after application of HES 130/0.4, a con-
venient sample of 25 inpatients of the Department of
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Otorhinolaryngology scheduled for routine applica-
tion of 500 mL 6% HES 130/0.4 in saline infusion (0.9%
NaCl) was evaluated. Furthermore, 15 healthy volun-
teers (i.e., employees of the St. John of God Hospital
Linz) receiving 500 mL saline infusion (0.9% NaCl)
served as controls. Exclusion criteria for the study
participants were history of HES exposition, volume
replacement therapy (e.g., dextrans, gelatins, albumin
solutions) or blood transfusions (e.g., erythrocyte
concentrates, fresh frozen plasma, platelets) within
2 weeks before enrolment into the present study, and
the presence of any comorbidities (with the exception
of arterial hypertension and diabetes mellitus).
The aim of the present study was to examine
whether the presence of HES 130/0.4 in blood sam-
ples affects the results of several common hematol-
ogy and clinical chemistry parameters. In case of an
interference resulting in a ‘‘clinically relevant differ-
ence’’ between values obtained in a distinct parame-
ter before and after HES 130/0.4 infusion, we
additionally aimed to investigate by application of in
vitro experiments (in vitro dilution of blood samples
by HES 130/0.4 vs. 0.9% NaCl in a 1:1 ratio) whether
this effect was masked (false) or pharmacological
(real) in nature. The definition of a ‘‘clinically relevant
difference’’ between values obtained in a distinct
parameter before and after HES 130/0.4 infusion was
based on the ‘‘reference change’’ concept for two suc-
cessive measurements, as described later in the sta-
tistical methods section. The study medication was
Voluven (HES 130/0.4) 6% infusion solution (Frese-
nius Kabi Austria GmbH, Graz, Austria). The main
physiochemical characteristics of Voluven (HES 130/
0.4) 6% infusion solution are as follows: average
mean molecular weight of 130 kDa; molar substitution
of 0.4; C2/C6 ratio of 9; HES concentration of 6%;
initial/distribution half-life ;1.4 h; and terminal/
elimination half-life ;12 h (24).
Eligible individuals were asked to participate in the
present study, and after appropriate information, they
signed the consent forms. The first blood collection
was carried out directly before HES 130/0.4 adminis-
tration (in patients) or saline infusion (in controls).
The duration of the infusion was 2–3 h by study
design in both patients and controls. Approximately
2 h (range 1–3 h) after the end of the infusion, blood
was collected from all study participants for the sec-
ond time. All hematology and clinical chemistry para-
meters of interest for the present study (listed in Table
1) were determined from the blood samples obtained
before and after the infusion. At each time point, the
necessary amount of Vacuette erythrocyte sedimen-
tation rate (ESR) sodium citrate, Vacuette EDTA K3,
Vacuette 3.8% sodium citrate and Vacuette serum clot
activator tubes (Greiner Bio-One, Kremsmuenster,
Austria) were collected. Additionally, each parameter
was determined in samples prepared by in vitro dilu-
tions of the blood collected from the patients before
HES 130/0.4 administration in a 1:1 ratio with Volu-
ven (HES 130/0.4) 6% infusion solution and saline
infusion solution (0.9% NaCl), respectively.
All laboratory analyses were performed within 2 h
after blood collection by commercially available pro-
cedures. ESR after 1 h was determined with a Sed
Rate Screener 100 (Greiner Bio-One, Kremsmuenster,
Austria); white blood cell counts, erythrocyte counts
and platelet counts, as well as determinations of
hemoglobin and mean cell volume were performed
with a Cell-Dyn 4000 system (Abbott Laboratories,
Abbott Park, IL, USA); prothrombin time according to
Quick, activated partial thromboplastin time, and
fibrinogen activity according to Clauss were meas-
ured on a BCS coagulation analyzer (Dade Behring,
Marburg, Germany) with Dade Behring reagents
(Thromborel S, Dade Actin FSL and Multifibren U,
respectively); and all clinical chemistry parameters
were assessed using serum samples by standardized
methods on a COBAS Integra 700 analyzer (Roche
Diagnostics, Mannheim, Germany). The following
methods were applied: creatinine – kinetic Jaffe reac-
tion without deproteinization (compensated method);
blood urea – kinetic test with urease and glutamate
dehydrogenase; sodium, potassium and chloride –
ion-selective electrodes; calcium – method according
to Schwarzenbach with o-cresolphthalein; phosphate
– direct phosphomolybdate method according to Daly
and Ertingshausen (25); uric acid – enzymatic colori-
metric test; bilirubin total – Diazo method; aspartate
aminotransferase and alanine aminotransferase –
method with pyridoxal-59-phosphate according to the
International Federation of Clinical Chemistry and
Laboratory Medicine (IFCC); g-glutamyl transpepti-
dase – enzymatic colorimetric assay according to the
IFCC; alkaline phosphatase – colorimetric assay
according to the IFCC; lactate dehydrogenase – opti-
mized standard method according to the German
Society of Clinical Chemistry (Deutsche Gesellschaft
fu¨r Klinische Chemie, DGKC); cholinesterase – meth-
od with S-butyrylthiocholine iodide; total creatine
kinase (CK) – method according to the IFCC; creatine
kinase muscle-brain type activity (CK-MB) – after
immunoinhibition with antibodies to the CK-M sub-
unit, the CK-B activity was determined with a method
according to the IFCC; a-amylase – enzymatic colori-
metric assay according to the IFCC; lipase – enzymatic
colorimetric assay with 1,2-O-dilauryl-rac-glycero-3-
glutaric acid-(6-methyl-resorufin) ester as substrate;
glucose – enzymatic reference method with hexoki-
nase; glycohemoglobin A1c (HbA1c) – total hemoglo-
bin and HbA1c were determined after hemolysis of
the anticoagulated blood specimen, total hemoglobin
was measured colorimetrically, HbA1c was deter-
mined immunoturbidimetrically, the ratio of both con-
centrations yielded the final percent HbA1c result;
total cholesterol – enzymatic colorimetric method;
high-density lipoprotein cholesterol and low-density
lipoprotein cholesterol – homogeneous enzymatic
colorimetric assays; triglycerides – enzymatic colori-
metric method with glycerol phosphate oxidase and
4-aminophenazone; C-reactive protein – particle
enhanced turbidimetric assay. HES serum concentra-
tions were measured using the hexokinase method as
previously described (26).
Statistical analysis was performed with the SPSS
software release 13.0 (SPSS Inc., Chicago, IL, USA).
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Data of hematology and clinical chemistry parameters
were expressed as median (25th–75th percentiles). In
patients with HES 130/0.4 administration and in con-
trols with saline infusion, differences between pre-
and post-infusion values were expressed as percent
change of the post-infusion values compared with the
pre-infusion values (applied for the data depicted in
Table 1). According to the ‘‘reference change’’ con-
cept for two successive measurements as mentioned
previously, a ‘‘clinically relevant difference’’ of values
obtained in a distinct parameter before and after HES
130/0.4 infusion was evident by definition, if the medi-
an percent change of the post-infusion values com-
pared with the pre-infusion values was greater than
the reference change value (RCV) for a specific
parameter. RCVs for each analyte are shown in
Table 1 and were calculated as follows (27):
RCVszp=62=6(CVW2 q CVA2), where zp is probability
density function (generally 1.96 at ps0.05 of both
side variations), CVW is within-subject biological var-
iation and CVA is analytical variation of the test. CVW
data were retrieved from the Westgard database
(http://www.westgard.com/biodatabase1.htm, date of
access 25 December 2007). Because no CVW for ESR
is listed in this database, we used a previously pub-
lished value (28). CVA data were retrieved from the
manufacturers’ package inserts or product hand-
books; in the case of more than one specification for
a certain test, we used the lowest value given.
Of the 25 patients (20 male, 5 female; median age
38 years, range 21–56 years) enrolled into the present
study, 13 had acute hearing loss, 10 had tinnitus, one
had vestibular syndrome and one had peripheral
facial palsy. One patient had concomitant arterial
hypertension and one had diabetes mellitus. The
median duration of the HES 130/0.4 infusion was 2.4 h
(range 2.1–2.9 h), and the median time interval
between the end of the HES 130/0.4 infusion and the
second blood withdrawal was 2.1 h (range 1.3–2.8 h).
The median serum HES concentration at the second
blood withdrawal was 0.20 g/dL (range 0.14–0.31
g/dL). In the 15 healthy controls (10 male, 5 female;
median age 35 years, range 21–52 years), the dura-
tion of the saline infusion and the time interval
between the end of the saline infusion and the second
blood withdrawal also complied with the study
protocol.
In Table 1, the pre- and post-infusion values of each
study parameter for both the patients and controls, as
well as the median difference of the post-infusion val-
ues compared with the pre-infusion values and the
RCVs are listed. In the patients, a median difference
greater than the RCV was observed only for serum
amylase. For this parameter, the median results
obtained from samples prepared by in vitro dilutions
of the blood collected from the patients before HES
130/0.4 administration in a 1:1 ratio with Voluven
(HES 130/0.4) 6% infusion solution and saline infusion
solution (0.9% NaCl), respectively, were 27 U/L (inter-
quartile range 23–33) and 27 U/L (interquartile range
23–38) with a median difference between those val-
ues (expressed as percent change compared to the
NaCl values) of 3%.
The main finding of the present study was that
serum amylase activity was the only parameter
among a battery of laboratory tests that was influ-
enced in a clinically relevant manner due to the pres-
ence of HES 130/0.4 in vivo in the patients evaluated.
Amylase activity increased by 85% in the blood sam-
ples obtained after intravenous administration of
500 mL Voluven (HES 130/0.4) 6% infusion solution
compared with the blood samples collected before
the colloid administration. As expected, in healthy
controls receiving 500 mL saline infusion no relevant
effect on amylase activity could be observed. Fur-
thermore, by applying in vitro experiments we dem-
onstrated that no relevant effect on serum amylase
activity was detectable by the presence of HES 130/
0.4 in diluted blood samples. Comparing the values
obtained in the samples diluted in a 1:1 ratio with HES
130/0.4 vs. the samples diluted in a 1:1 ratio with 0.9%
NaCl (both derived from the 25 patients before the
infusion HES 130/0.4), a negligible median difference
of 3% was observed for this parameter.
Considering these issues, we conclude that the in
vivo effects of HES 130/0.4 administration on amylase
activity observed in our study was pharmacological
(real) in nature. Our results argue, therefore, against
an interference of HES 130/0.4 itself with the analyti-
cal procedure of this laboratory test. This conclusion
is supported by the in vitro experiment, where only
3% variation was observed after a 1:1 dilution of the
specimens with HES, which contrasts with the larger
bias recorded ex vivo.
A major limitation, however, regarding the possi-
bility of generalizing our study results is the fact that
we used distinct laboratory methods for the present
work as described above, and it is thus possible that
using other platforms or other analytical procedures
might yield other effects. Therefore, the reproduction
of our results in other centers or by multicenter stud-
ies would argue for their validity.
The 4% decrease of hemoglobin and erythrocytes
induced by the infusion of 500 mL 6% HES 130/0.4
indicates a volume expanding effect of approximately
200 mL at the time of the second examination ;4.5 h
after starting the colloid application. This is in accor-
dance with the pharmacological properties of HES
130/0.4 which suggest relevant volume efficacy of a
6% solution for some hours also in situations without
initial volume deficit (29, 30). Bearing in mind the
complex process of volume normalization after hyper-
volemic infusion (31), the HES serum concentrations
obtained after administration of 500 mL Voluven
(HES 130/0.4) 6% infusion solution in our study sug-
gest a residual colloid amount of approximately one-
quarter of the infused 30 g at the time point of the
second blood collection, thus being consistent with
our above described clinical observations. As not all
examined parameters can be considered to decrease
linearly with plasma volume changes, we arbitrarily
compared the values of the first and the second
examination without dilution adjustment, which
might be considered another limitation of the study.
In this context, it is important to emphasize that the
Bereitgestellt von | Universitaetsbibliothek der LMU Muenchen
Angemeldet | 129.187.254.47
Heruntergeladen am | 14.11.13 15:57
562 Mueller et al.: Influence of HES on laboratory parameters
Article in press - uncorrected proof
present evaluation was based on the single adminis-
tration of 500 mL 6% HES 130/0.4 for the purpose of
rheological therapy. Hence, the results obtained in
this work may not be extrapolated in clinical situa-
tions where volume substitution is necessary (i.e.,
infusion of higher HES doses in intensive care or
emergency medicine).
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